2009
Haws LC , DeVito MJ, Walker NJ, Birnbaum LS, Farland WH, Harris MA , Tachovsky JA, Unice KM, Scott PK, Staskal-Wikoff DF . 2009. Development of distributions of relative potency estimates to quantitatively assess uncertainty inherent in the TEFs for dioxin-like compounds: A proposed consensus-based weighting. Presented at Dioxin 2009, Beijing, China.
Staskal-Wikoff DF , Harris MA , Haws LC , Birnbaum LS, Tachovsky JA. 2009. Probabilistic evaluation of cancer and non-cancer risk associated with exposure to BDE 209 in automobiles. Presented at Dioxin 2009. Beijing, China.
Urban JD , Tachovsky JA, Staskal DF, Haws LC , Harris MA . 2009. Human health risk assessment of consumption of fish from the Lower Passaic River. Presented at the 48th Annual Meeting of Society for Toxicology, March 15-19, Baltimore, MD.
Mounho B. 2009. Small molecule and biological therapeutics: History and inherent differences. Presented at Cambridge Healthtech Institute’s PEGS Summit, April 6-10, Boston, MA.
Mounho B. 2009. Preclinical toxicology studies to support the development of monoclonal abs: Scientific issues and challenges. Presented at Cambridge Healthtech Institute’s PEGS Summit, April 6-10, Boston, MA.
Mounho B. 2009. Scientific challenges in preclinical studies to support the clinical development of biologics. Presented at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference, February 25-27, San Francisco, CA.
Mounho B. 2009. Preclinical development of biologics. Presented at Cambridge Healthtech Institute’s Molecular Medicine Tri-Conference, February 25-27, San Francisco, CA.
Mounho B. 2009. Comparability challenges: Regulatory and scientific issues in the assessment of biopharmaceuticals. Presented at Drug Information Association Meeting.
Mounho B. 2009. Nonclinical safety assessment studies to support manufacturing process changes for Vectibix®. Presented at Drug Information Association Meeting.
2008
Harris MA Tachovsky JA , Williams ES, Paustenbach DP, Haws LC
